Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
Descriptor ID |
D057911
|
MeSH Number(s) |
D27.505.519.162
|
Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 1 | 0 | 1 |
1999 | 1 | 1 | 2 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 2 | 2 | 4 |
2005 | 0 | 1 | 1 |
2007 | 4 | 0 | 4 |
2008 | 0 | 1 | 1 |
2009 | 1 | 1 | 2 |
2011 | 5 | 1 | 6 |
2012 | 2 | 0 | 2 |
2013 | 3 | 2 | 5 |
2014 | 3 | 3 | 6 |
2015 | 2 | 2 | 4 |
2016 | 3 | 3 | 6 |
2017 | 4 | 3 | 7 |
2018 | 3 | 2 | 5 |
2019 | 3 | 3 | 6 |
2020 | 6 | 4 | 10 |
2021 | 1 | 7 | 8 |
2022 | 1 | 7 | 8 |
2023 | 1 | 7 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
-
Trajectories of adherence to ACEI/ARB medications following a motivational interviewing intervention among Medicare Advantage beneficiaries in Texas. Patient Educ Couns. 2024 Feb; 119:108073.
-
How do we define high and low dose intensity of heart failure medications: a scoping review. BMC Cardiovasc Disord. 2023 09 27; 23(1):478.
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
-
Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
-
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. J Am Heart Assoc. 2023 04 04; 12(7):e028278.
-
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
-
A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes. Drugs Aging. 2023 04; 40(4):377-390.
-
Heart?Failure Drug Treatment-Inertia,?Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 01; 11(1):1-14.
-
Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc. 2022 09; 97(9):1734-1751.